A Study to Evaluate High Eradication Rate of Vonoprazan-based triple therapy Compared to Esomeprazole (EO) -based therapy in Patients Infected with H. pylori who are Resistant to Clarithromycin

Trial Profile

A Study to Evaluate High Eradication Rate of Vonoprazan-based triple therapy Compared to Esomeprazole (EO) -based therapy in Patients Infected with H. pylori who are Resistant to Clarithromycin

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs Vonoprazan (Primary) ; Amoxicillin; Clarithromycin; Esomeprazole
  • Indications Helicobacter pylori infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jun 2016 New trial record
    • 24 May 2016 Results presented at the Digestive Disease Week 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top